Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency
Phase of Trial: Phase II
Latest Information Update: 09 Apr 2019
Price : $35 *
At a glance
- Drugs SGS 742 (Primary)
- Indications Inborn error amino acid metabolic disorders
- Focus Therapeutic Use
- 05 Apr 2019 Status changed from active, no longer recruiting to completed.
- 15 Feb 2019 Planned End Date changed from 31 Jan 2019 to 31 Jan 2020.
- 31 Aug 2018 Biomarkers information updated